

# EMEA (Europe, Middle East and Africa) Checkpoint Inhibitors for Treating Cancer Market Report 2017

<https://marketpublishers.com/r/EECD33CF2AEEN.html>

Date: December 2017

Pages: 104

Price: US\$ 4,000.00 (Single User License)

ID: EECD33CF2AEEN

## Abstracts

In this report, the EMEA Checkpoint Inhibitors for Treating Cancer market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Units), revenue (Million USD), market share and growth rate of Checkpoint Inhibitors for Treating Cancer for these regions, from 2012 to 2022 (forecast)

Europe: Germany, France, UK, Russia, Italy and Benelux;

Middle East: Saudi Arabia, Israel, UAE and Iran;

Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Checkpoint Inhibitors for Treating Cancer market competition by top manufacturers/players, with Checkpoint Inhibitors for Treating Cancer sales volume (K Units), price (USD/Unit), revenue (Million USD) and market share for each manufacturer/player; the top players including

Bristol-Myers Squibb(BMS)

Merck

Roche

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into

PD-1 inhibitors

PD-L1 inhibitors

CTLA-4 inhibitors

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including

Melanoma Treatment

Bladder Cancer Treatment

Other

If you have any special requirements, please let us know and we will offer you the report as you want.

## Contents

EMEA (Europe, Middle East and Africa) Checkpoint Inhibitors for Treating Cancer Market Report 2017

### **1 CHECKPOINT INHIBITORS FOR TREATING CANCER OVERVIEW**

1.1 Product Overview and Scope of Checkpoint Inhibitors for Treating Cancer

1.2 Classification of Checkpoint Inhibitors for Treating Cancer

1.2.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Sales)

Comparison by Type (2012-2022)

1.2.2 EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Sales) Market Share by Type (Product Category) in 2016

1.2.3 PD-1 inhibitors

1.2.4 PD-L1 inhibitors

1.2.5 CTLA-4 inhibitors

1.3 EMEA Checkpoint Inhibitors for Treating Cancer Market by Application/End Users

1.3.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales (Volume) and Market Share Comparison by Application (2012-2022)

1.3.2 Melanoma Treatment

1.3.3 Bladder Cancer Treatment

1.3.4 Other

1.4 EMEA Checkpoint Inhibitors for Treating Cancer Market by Region

1.4.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Value) Comparison by Region (2012-2022)

1.4.2 Europe Status and Prospect (2012-2022)

1.4.3 Middle East Status and Prospect (2012-2022)

1.4.4 Africa Status and Prospect (2012-2022)

1.5 EMEA Market Size (Value and Volume) of Checkpoint Inhibitors for Treating Cancer (2012-2022)

1.5.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2022)

1.5.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2022)

### **2 EMEA CHECKPOINT INHIBITORS FOR TREATING CANCER COMPETITION BY MANUFACTURERS/PLAYERS/SUPPLIERS, REGION, TYPE AND APPLICATION**

2.1 EMEA Checkpoint Inhibitors for Treating Cancer Market Competition by

## Players/Manufacturers

2.1.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume and Market Share of Major Players (2012-2017)

2.1.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Share by Players (2012-2017)

2.1.3 EMEA Checkpoint Inhibitors for Treating Cancer Sale Price by Players (2012-2017)

2.2 EMEA Checkpoint Inhibitors for Treating Cancer (Volume and Value) by Type/Product Category

2.2.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type (2012-2017)

2.2.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Type (2012-2017)

2.2.3 EMEA Checkpoint Inhibitors for Treating Cancer Sale Price by Type (2012-2017)

2.3 EMEA Checkpoint Inhibitors for Treating Cancer (Volume) by Application

2.4 EMEA Checkpoint Inhibitors for Treating Cancer (Volume and Value) by Region

2.4.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Region (2012-2017)

2.4.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Market Share by Region (2012-2017)

2.4.3 EMEA Checkpoint Inhibitors for Treating Cancer Sales Price by Region (2012-2017)

## **3 EUROPE CHECKPOINT INHIBITORS FOR TREATING CANCER (VOLUME, VALUE AND SALES PRICE), BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

3.1 Europe Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)

3.1.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)

3.1.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)

3.2 Europe Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type

3.3 Europe Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application

3.4 Europe Checkpoint Inhibitors for Treating Cancer Sales Volume and Value (Revenue) by Countries

3.4.1 Europe Checkpoint Inhibitors for Treating Cancer Sales Volume by Countries (2012-2017)

3.4.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2012-2017)

3.4.3 Germany Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

3.4.4 France Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

3.4.5 UK Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

3.4.6 Russia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

3.4.7 Italy Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

3.4.8 Benelux Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

#### **4 MIDDLE EAST CHECKPOINT INHIBITORS FOR TREATING CANCER (VOLUME, VALUE AND SALES PRICE), BY REGION, TYPE AND APPLICATION**

4.1 Middle East Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)

4.1.1 Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)

4.1.2 Middle East Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)

4.2 Middle East Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type

4.3 Middle East Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application

4.4 Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume and Value (Revenue) by Countries

4.4.1 Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume by Countries (2012-2017)

4.4.2 Middle East Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2012-2017)

4.4.3 Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

4.4.4 Israel Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

4.4.5 UAE Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

4.4.6 Iran Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

## **5 AFRICA CHECKPOINT INHIBITORS FOR TREATING CANCER (VOLUME, VALUE AND SALES PRICE) BY PLAYERS, COUNTRIES, TYPE AND APPLICATION**

5.1 Africa Checkpoint Inhibitors for Treating Cancer Sales and Value (2012-2017)

5.1.1 Africa Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2017)

5.1.2 Africa Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)

5.2 Africa Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Type

5.3 Africa Checkpoint Inhibitors for Treating Cancer Sales and Market Share by Application

5.4 Africa Checkpoint Inhibitors for Treating Cancer Sales Volume and Value (Revenue) by Countries

5.4.1 Africa Checkpoint Inhibitors for Treating Cancer Sales Volume by Countries (2012-2017)

5.4.2 Africa Checkpoint Inhibitors for Treating Cancer Revenue by Countries (2012-2017)

5.4.3 South Africa Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

5.4.4 Nigeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

5.4.5 Egypt Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

5.4.6 Algeria Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate (2012-2017)

## **6 EMEA CHECKPOINT INHIBITORS FOR TREATING CANCER MANUFACTURERS/PLAYERS PROFILES AND SALES DATA**

6.1 Bristol-Myers Squibb(BMS)

6.1.1 Company Basic Information, Manufacturing Base and Competitors

6.1.2 Checkpoint Inhibitors for Treating Cancer Product Type, Application and Specification

6.1.2.1 Product A

6.1.2.2 Product B

6.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales,

## Revenue, Price and Gross Margin (2012-2017)

### 6.1.4 Main Business/Business Overview

## 6.2 Merck

### 6.2.1 Company Basic Information, Manufacturing Base and Competitors

### 6.2.2 Checkpoint Inhibitors for Treating Cancer Product Type, Application and Specification

#### 6.2.2.1 Product A

#### 6.2.2.2 Product B

### 6.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)

### 6.2.4 Main Business/Business Overview

## 6.3 Roche

### 6.3.1 Company Basic Information, Manufacturing Base and Competitors

### 6.3.2 Checkpoint Inhibitors for Treating Cancer Product Type, Application and Specification

#### 6.3.2.1 Product A

#### 6.3.2.2 Product B

### 6.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue, Price and Gross Margin (2012-2017)

### 6.3.4 Main Business/Business Overview

## **7 CHECKPOINT INHIBITORS FOR TREATING CANCER MANUFACTURING COST ANALYSIS**

### 7.1 Checkpoint Inhibitors for Treating Cancer Key Raw Materials Analysis

#### 7.1.1 Key Raw Materials

#### 7.1.2 Price Trend of Key Raw Materials

#### 7.1.3 Key Suppliers of Raw Materials

#### 7.1.4 Market Concentration Rate of Raw Materials

### 7.2 Proportion of Manufacturing Cost Structure

#### 7.2.1 Raw Materials

#### 7.2.2 Labor Cost

#### 7.2.3 Manufacturing Expenses

### 7.3 Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

## **8 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS**

### 8.1 Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis

### 8.2 Upstream Raw Materials Sourcing

8.3 Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Manufacturers in 2016

8.4 Downstream Buyers

## **9 MARKETING STRATEGY ANALYSIS, DISTRIBUTORS/TRADERS**

9.1 Marketing Channel

9.1.1 Direct Marketing

9.1.2 Indirect Marketing

9.1.3 Marketing Channel Development Trend

9.2 Market Positioning

9.2.1 Pricing Strategy

9.2.2 Brand Strategy

9.2.3 Target Client

9.3 Distributors/Traders List

## **10 MARKET EFFECT FACTORS ANALYSIS**

10.1 Technology Progress/Risk

10.1.1 Substitutes Threat

10.1.2 Technology Progress in Related Industry

10.2 Consumer Needs/Customer Preference Change

10.3 Economic/Political Environmental Change

## **11 EMEA CHECKPOINT INHIBITORS FOR TREATING CANCER MARKET FORECAST (2017-2022)**

11.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Price Forecast (2017-2022)

11.1.1 EMEA Checkpoint Inhibitors for Treating Cancer Sales and Growth Rate Forecast (2017-2022)

11.1.2 EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate Forecast (2017-2022)

11.1.3 EMEA Checkpoint Inhibitors for Treating Cancer Price and Trend Forecast (2017-2022)

11.2 EMEA Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.3 Europe Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)



11.4 Middle Eastt Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.5 Africa Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Growth Rate Forecast by Region (2017-2022)

11.6 EMEA Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2017-2022)

11.7 EMEA Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2017-2022)

## **12 RESEARCH FINDINGS AND CONCLUSION**

## **13 APPENDIX**

13.1 Methodology/Research Approach

13.1.1 Research Programs/Design

13.1.2 Market Size Estimation

13.1.3 Market Breakdown and Data Triangulation

13.2 Data Source

13.2.1 Secondary Sources

13.2.2 Primary Sources

13.3 Disclaimer

The report requires updating with new data and is sent in 2-3 business days after order is placed.

## List Of Tables

### LIST OF TABLES AND FIGURES

- Figure Product Picture of Checkpoint Inhibitors for Treating Cancer
- Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) by Type (2012-2022)
- Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Type (Product Category) in 2016
- Figure PD-1 inhibitors Product Picture
- Figure PD-L1 inhibitors Product Picture
- Figure CTLA-4 inhibitors Product Picture
- Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) by Application (2012-2022)
- Figure EMEA Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application in 2016
- Figure Melanoma Treatment Examples
- Table Key Downstream Customer in Melanoma Treatment
- Figure Bladder Cancer Treatment Examples
- Table Key Downstream Customer in Bladder Cancer Treatment
- Figure Other Examples
- Table Key Downstream Customer in Other
- Figure EMEA Checkpoint Inhibitors for Treating Cancer Market Size (Million USD) by Region (2012-2022)
- Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Status and Forecast by Countries
- Figure Middle East Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Middle East Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Status and Forecast by Countries
- Figure Africa Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2022)
- Figure Africa Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Status and Forecast by Countries
- Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume and Growth Rate (2012-2022)
- Figure EMEA Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and

Growth Rate (2012-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Market Major Players Product Sales Volume (K Units) (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) of Major Players (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales Share by Players (2012-2017)

Figure 2016 Checkpoint Inhibitors for Treating Cancer Sales Share by Players

Figure 2017 Checkpoint Inhibitors for Treating Cancer Sales Share by Players

Figure EMEA Checkpoint Inhibitors for Treating Cancer Market Major Players Product Revenue (Million USD) (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Players (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue Share by Players (2012-2017)

Table 2016 EMEA Checkpoint Inhibitors for Treating Cancer Revenue Share by Players

Table 2017 EMEA Checkpoint Inhibitors for Treating Cancer Revenue Share by Players

Table EMEA Checkpoint Inhibitors for Treating Cancer Sale Price (USD/Unit) by Players (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Market Share by Type (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2012-2017)

Figure Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Type (2012-2017)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Market Share by Type (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2012-2017)

Figure Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Type in 2016

Table EMEA Checkpoint Inhibitors for Treating Cancer Sale Price (USD/Unit) by Type (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Market Share by Application (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2012-2017)

Figure Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Application (2012-2017)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2016

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Market Share by Region (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales Share by Region (2012-2017)

Figure Sales Market Share of Checkpoint Inhibitors for Treating Cancer by Region (2012-2017)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Market Share in 2016

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Market Share by Region (2012-2017)

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue Share by Region (2012-2017)

Figure Revenue Market Share of Checkpoint Inhibitors for Treating Cancer by Region (2012-2017)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Revenue Market Share Regions in 2016

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales Price (USD/Unit) by Region (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate (2012-2017)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Type (2012-2017)

Table Europe Checkpoint Inhibitors for Treating Cancer Market Share by Type (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Market Share by Type in 2016

Table Europe Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Application (2012-2017)

Table Europe Checkpoint Inhibitors for Treating Cancer Market Share by Application (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Market Share by Application in 2016

Table Europe Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Countries (2012-2017)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by

Countries (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2016

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Countries (2012-2017)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2012-2017)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2016

Figure Germany Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure France Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure UK Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Russia Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Italy Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Benelux Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2017)

Table Middle East Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Type (2012-2017)

Table Middle East Checkpoint Inhibitors for Treating Cancer Market Share by Type (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Market Share by Type (2012-2017)

Table Middle East Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Applications (2012-2017)

Table Middle East Checkpoint Inhibitors for Treating Cancer Market Share by Applications (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2016

Table Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) by Countries (2012-2017)

Table Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Countries (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Sales Volume Market Share by Countries in 2016

Table Middle East Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Countries (2012-2017)

Table Middle East Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2012-2017)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2016

Figure Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Israel Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure UAE Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Iran Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) and Growth Rate (2012-2017)

Table Africa Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Type (2012-2017)

Table Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2016

Table Africa Checkpoint Inhibitors for Treating Cancer Sales (K Units) by Application (2012-2017)

Table Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by

Application (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2012-2017)

Table Africa Checkpoint Inhibitors for Treating Cancer Sales Volume (K Units) by Countries (2012-2017)

Table Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Countries in 2016

Table Africa Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) by Countries (2012-2017)

Table Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries (2012-2017)

Figure Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Countries in 2016

Figure South Africa Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Nigeria Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Egypt Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Algeria Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Basic Information List

Table Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales Market Share in EMEA (2012-2017)

Figure Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Revenue Market Share in EMEA (2012-2017)

Table Merck Checkpoint Inhibitors for Treating Cancer Basic Information List

Table Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (Million

USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Merck Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Merck Checkpoint Inhibitors for Treating Cancer Sales Market Share in EMEA (2012-2017)

Figure Merck Checkpoint Inhibitors for Treating Cancer Revenue Market Share in EMEA (2012-2017)

Table Roche Checkpoint Inhibitors for Treating Cancer Basic Information List

Table Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units), Revenue (Million USD), Price (USD/Unit) and Gross Margin (2012-2017)

Figure Roche Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate (2012-2017)

Figure Roche Checkpoint Inhibitors for Treating Cancer Sales Market Share in EMEA (2012-2017)

Figure Roche Checkpoint Inhibitors for Treating Cancer Revenue Market Share in EMEA (2012-2017)

Table Production Base and Market Concentration Rate of Raw Material

Figure Price Trend of Key Raw Materials

Table Key Suppliers of Raw Materials

Figure Manufacturing Cost Structure of Checkpoint Inhibitors for Treating Cancer

Figure Manufacturing Process Analysis of Checkpoint Inhibitors for Treating Cancer

Figure Checkpoint Inhibitors for Treating Cancer Industrial Chain Analysis

Table Raw Materials Sources of Checkpoint Inhibitors for Treating Cancer Major Manufacturers in 2016

Table Major Buyers of Checkpoint Inhibitors for Treating Cancer

Table Distributors/Traders List

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) and Growth Rate Forecast (2017-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Revenue and Growth Rate Forecast (2017-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Price (USD/Unit) and Trend Forecast (2017-2022)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) Forecast by Region (2017-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2017-2022)

Table EMEA Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Forecast by Region (2017-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Revenue Market Share



Forecast by Region (2017-2022)

Table Europe Checkpoint Inhibitors for Treating Cancer Sales (K Units) Forecast by Countries (2017-2022)

Figure Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Countries (2017-2022)

Table Europe Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Countries (2017-2022)

Table Middle East Checkpoint Inhibitors for Treating Cancer Sales (K Units) Forecast by Countries (2017-2022)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Countries (2017-2022)

Table Middle East Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Middle East Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Countries (2017-2022)

Table Africa Checkpoint Inhibitors for Treating Cancer Sales (K Units) Forecast by Countries (2017-2022)

Figure Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Countries (2017-2022)

Table Africa Checkpoint Inhibitors for Treating Cancer Revenue (Million USD) Forecast by Countries (2017-2022)

Figure Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Countries (2017-2022)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) Forecast by Type (2017-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2017-2022)

Table EMEA Checkpoint Inhibitors for Treating Cancer Sales (K Units) Forecast by Application (2017-2022)

Figure EMEA Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2017-2022)

Table Research Programs/Design for This Report

Figure Bottom-up and Top-down Approaches for This Report

Figure Data Triangulation

Table Key Data Information from Secondary Sources

Table Key Data Information from Primary Sources

## I would like to order

Product name: EMEA (Europe, Middle East and Africa) Checkpoint Inhibitors for Treating Cancer Market Report 2017

Product link: <https://marketpublishers.com/r/EECD33CF2AEEN.html>

Price: US\$ 4,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/EECD33CF2AEEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

